Cardiff Oncology (CRDF) Expected to Announce Quarterly Earnings on Thursday

Cardiff Oncology (NASDAQ:CRDF) is anticipated to post its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Cardiff Oncology to post earnings of ($0.18) per share for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, March 6, 2026 at 4:00 PM ET.

Cardiff Oncology Stock Performance

Cardiff Oncology stock opened at $1.56 on Tuesday. Cardiff Oncology has a one year low of $1.48 and a one year high of $4.86. The stock has a fifty day moving average of $2.37 and a 200 day moving average of $2.26. The stock has a market cap of $105.08 million, a PE ratio of -1.97 and a beta of 1.33.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Brooklyn Investment Group purchased a new stake in shares of Cardiff Oncology in the third quarter worth about $26,000. Engineers Gate Manager LP bought a new stake in Cardiff Oncology in the 2nd quarter worth approximately $43,000. BNP Paribas Financial Markets raised its holdings in shares of Cardiff Oncology by 335.1% during the 2nd quarter. BNP Paribas Financial Markets now owns 15,437 shares of the company’s stock worth $49,000 after acquiring an additional 11,889 shares in the last quarter. Raymond James Financial Inc. boosted its position in shares of Cardiff Oncology by 70.1% during the 3rd quarter. Raymond James Financial Inc. now owns 23,632 shares of the company’s stock valued at $49,000 after acquiring an additional 9,740 shares during the last quarter. Finally, The Manufacturers Life Insurance Company boosted its position in shares of Cardiff Oncology by 23.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 21,956 shares of the company’s stock valued at $69,000 after acquiring an additional 4,232 shares during the last quarter. Hedge funds and other institutional investors own 16.29% of the company’s stock.

Wall Street Analyst Weigh In

CRDF has been the topic of several recent research reports. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Cardiff Oncology in a research note on Wednesday, January 28th. Noble Financial began coverage on shares of Cardiff Oncology in a research report on Monday, January 5th. They issued an “outperform” rating and a $12.00 price target on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Cardiff Oncology in a research note on Wednesday, January 21st. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $11.13.

About Cardiff Oncology

Cardiff Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development.